凝血酶受体（蛋白酶激活受体-1）拮抗剂作为具有强大抗血小板作用的强效抗血栓形成药物。 - Suppr

Suppr

超能文献

Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.

作者信息

Chackalamannil Samuel

机构信息

Schering-Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, USA. samuel.

出版信息

J Med Chem. 2006 Sep 7;49(18):5389-403. doi: 10.1021/jm0603670.

DOI:10.1021/jm0603670

PMID:16942011

Abstract

摘要

相似文献

Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects.凝血酶受体（蛋白酶激活受体-1）拮抗剂作为具有强大抗血小板作用的强效抗血栓形成药物。

J Med Chem. 2006 Sep 7;49(18):5389-403. doi: 10.1021/jm0603670.

Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring.源自辛巴辛的凝血酶受体（PAR-1）拮抗剂：吡啶环的构效关系

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13. doi: 10.1016/j.bmcl.2007.06.002. Epub 2007 Jun 15.

Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents.发现强效口服活性凝血酶受体（蛋白酶激活受体1）拮抗剂作为新型抗血栓药物。

J Med Chem. 2005 Sep 22;48(19):5884-7. doi: 10.1021/jm0502236.

Heterotricyclic himbacine analogs as potent, orally active thrombin receptor (protease activated receptor-1) antagonists.作为强效口服活性凝血酶受体（蛋白酶激活受体-1）拮抗剂的杂三环海巴辛类似物。

J Med Chem. 2007 Oct 18;50(21):5147-60. doi: 10.1021/jm070704k. Epub 2007 Sep 14.

Anticoagulant and antithrombotic properties of intracellular protease-activated receptor antagonists.细胞内蛋白酶激活受体拮抗剂的抗凝和抗血栓形成特性。

J Thromb Haemost. 2007 Mar;5(3):571-6. doi: 10.1111/j.1538-7836.2007.02364.x. Epub 2006 Dec 13.

Himbacine derived thrombin receptor antagonists: discovery of a new tricyclic core.源自辛贝碱的凝血酶受体拮抗剂：一种新型三环核心结构的发现。

Bioorg Med Chem Lett. 2007 Jul 1;17(13):3647-51. doi: 10.1016/j.bmcl.2007.04.061. Epub 2007 Apr 25.

Himbacine derived thrombin receptor (PAR-1) antagonists: structure-activity relationship of the lactone ring.源自辛巴生的凝血酶受体（PAR-1）拮抗剂：内酯环的构效关系

Bioorg Med Chem Lett. 2006 Sep 15;16(18):4969-72. doi: 10.1016/j.bmcl.2006.06.042. Epub 2006 Jul 7.

Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.新型喹啉类凝血酶受体（PAR-1）拮抗剂的发现与合成

Bioorg Med Chem Lett. 2006 Mar 15;16(6):1544-8. doi: 10.1016/j.bmcl.2005.12.042. Epub 2005 Dec 27.

New antithrombotic drugs.新型抗血栓药物。

Clin Pharmacol Ther. 2009 Aug;86(2):139-46. doi: 10.1038/clpt.2009.98. Epub 2009 Jun 24.

Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.

J Med Chem. 2005 May 5;48(9):3110-3. doi: 10.1021/jm048984g.

引用本文的文献

Therapeutic management of ischemic stroke.缺血性脑卒中的治疗管理。

Naunyn Schmiedebergs Arch Pharmacol. 2024 May;397(5):2651-2679. doi: 10.1007/s00210-023-02804-y. Epub 2023 Nov 15.

Recent advance in treatment of atherosclerosis: Key targets and plaque-positioned delivery strategies.动脉粥样硬化治疗的最新进展：关键靶点与斑块定位递送策略。

J Tissue Eng. 2022 Mar 24;13:20417314221088509. doi: 10.1177/20417314221088509. eCollection 2022 Jan-Dec.

Effects of the PAR-1 Antagonist Vorapaxar on Platelet Activation and Coagulation Biomarkers in Patients with Stable Coronary Artery Disease.PAR-1拮抗剂沃拉帕沙对稳定型冠状动脉疾病患者血小板活化及凝血生物标志物的影响

TH Open. 2019 Aug 16;3(3):e259-e262. doi: 10.1055/s-0039-1695710. eCollection 2019 Jul.

Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y inhibitors.强效P2Y抑制剂治疗的急性冠状动脉综合征患者中蛋白酶激活受体介导的血小板聚集

Res Pract Thromb Haemost. 2019 May 22;3(3):383-390. doi: 10.1002/rth2.12213. eCollection 2019 Jul.

Five Indigenous Plants of Pakistan with Antinociceptive, Anti-Inflammatory, Antidepressant, and Anticoagulant Properties in Sprague Dawley Rats.巴基斯坦的五种本土植物对斯普拉格-道利大鼠具有抗伤害感受、抗炎、抗抑郁和抗凝血特性。

Evid Based Complement Alternat Med. 2017;2017:7849501. doi: 10.1155/2017/7849501. Epub 2017 Nov 23.

Medical Treatment of Intracranial Atherosclerosis: An Update.颅内动脉粥样硬化的医学治疗：最新进展

J Stroke. 2017 Sep;19(3):261-270. doi: 10.5853/jos.2017.01830. Epub 2017 Sep 29.

Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar.选择性血小板抑制在降低心血管风险中的作用——沃拉帕沙的作用

Vasc Health Risk Manag. 2016 Jun 14;12:263-8. doi: 10.2147/VHRM.S81342. eCollection 2016.

The characteristics of thrombin in osteoarthritic pathogenesis and treatment.凝血酶在骨关节炎发病机制及治疗中的特性

Biomed Res Int. 2014;2014:407518. doi: 10.1155/2014/407518. Epub 2014 Sep 16.

Himbacine-derived thrombin receptor antagonists: c7-spirocyclic analogues of vorapaxar.源自辛巴生的凝血酶受体拮抗剂：沃拉帕沙的C7-螺环类似物。

ACS Med Chem Lett. 2014 Mar 11;5(5):561-5. doi: 10.1021/ml500008w. eCollection 2014 May 8.

Himbacine-derived thrombin receptor antagonists: c7-aminomethyl and c9a-hydroxy analogues of vorapaxar.源自himbacine的凝血酶受体拮抗剂：vorapaxar的C7-氨甲基和C9a-羟基类似物。

ACS Med Chem Lett. 2013 Dec 18;5(2):183-7. doi: 10.1021/ml400452v. eCollection 2014 Feb 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验